These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29370781)

  • 1. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
    Battaglin F; Schirripa M; Buggin F; Pietrantonio F; Morano F; Boscolo G; Tonini G; Lutrino ES; Lucchetti J; Salvatore L; Passardi A; Cremolini C; Arnoldi E; Scartozzi M; Pella N; Boni L; Bergamo F; Zagonel V; Loupakis F; Lonardi S
    BMC Cancer; 2018 Jan; 18(1):98. PubMed ID: 29370781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
    Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; Briscoe K; Srivastav R; Shannon J; Segelov E; Tie J; Caird S; Francesconi A; Price T; Wuttke M; Ladwa R; Sjoquist K; Burge M
    BMC Cancer; 2021 Aug; 21(1):932. PubMed ID: 34407800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
    Lonardi S; Rasola C; Lobefaro R; Rossini D; Formica V; Scartozzi M; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Pella N; Bergamo F; Raimondi A; Arnoldi E; Antonuzzo L; Granetto C; Zustovich F; Ronzoni M; Leo S; Morano F; Loupakis F; Buggin F; Zagonel V; Fassan M; Cremolini C; Boni L; Pietrantonio F;
    J Clin Oncol; 2023 Dec; 41(34):5263-5273. PubMed ID: 37535876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
    Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
    Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
    Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C
    J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
    Pietrantonio F; Cremolini C; Aprile G; Lonardi S; Orlandi A; Mennitto A; Berenato R; Antoniotti C; Casagrande M; Marsico V; Marmorino F; Cardellino GG; Bergamo F; Tomasello G; Formica V; Longarini R; Giommoni E; Caporale M; Di Bartolomeo M; Loupakis F; de Braud F
    Oncologist; 2015 Nov; 20(11):1261-5. PubMed ID: 26446234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
    Aparicio J; Virgili Manrique AC; Capdevila J; Muñoz Boza F; Galván P; Richart P; Oliveres H; Páez D; Hernando J; Serrano S; Vera R; Hernandez-Yagüe X; Gallego RÁ; Riesco-Martinez MC; García de Albeniz X; Maurel J
    Clin Transl Oncol; 2022 Nov; 24(11):2155-2165. PubMed ID: 35761123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
    Hebart H; Kiehl M; Tomasek J; Csoszi T; Koukakis R; Kafatos G; Kuhn A; Bjorklof K; Demonty G; Buchler T
    Adv Ther; 2019 Mar; 36(3):670-683. PubMed ID: 30689133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.